MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind expects to submit a request for a supplemental new ...
Hosted on MSN23d
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...
The insulin called Afrezza is created and manufactured by MannKind Corporation, and is used to improve glycemic control in adults with diabetes mellitus.“Afrezza is a rapid-acting insulin ...
The INHALE-1 study is a 26-week, open-label clinical trial that randomized 230 subjects to one of two groups: Afrezza or multiple daily injections (MDI) of rapid acting insulin analog (RAA ...
The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide ...
Mannkind Corporation expects to submit a request for a supplemental new drug application meeting to the US Food and Drug Administration for its inhaled human insulin (Afrezza Inhalation Powder).
The CDSCO decision follows existing approvals in the United States and Brazil. “Achieving approval for Afrezza in India, a country with the second highest burden of diabetes worldwide, is an exciting ...
MannKind (MNKD) and Cipla announced that the Central Drugs Standard Control Organisation in India has approved Afrezza Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback